2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
01/23/19New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model
Landmark preclinical lactation study of unique form of vitamin B3 (nicotinamide riboside) showing remarkable results in rodents published in Cell Reports LOS ANGELES, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring physiological benefits to mothers and offspring. Conduct... 
Printer Friendly Version
01/22/19ChromaDex Prepared to Proceed with Patent Infringement Action Against Elysium Health
ChromaDex to move forward with patent infringement action, following unsuccessful challenge by Elysium Health during Inter Partes Review (IPR) LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported the rejection of Elysium Health Inc.’s challenge to Claim 2 of U.S. Patent No. 8,383,086 ("the '086 patent") by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.  ChromaDex reported on January 22, 2018 that the PTAB denied Elysium... 
Printer Friendly Version